Clinical Trials on Columnar Cell Variant Thyroid Gland Papillary Carcinoma

Total 3337 results

Translational Research Center for Medical Innovation...
Okayama University; Japanese Gynecologic Oncology Group (JGOG)

Recruiting

Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2

Fallopian Tube Carcinoma | Peritoneal Carcinoma | Ovarian Carcinoma | BRCA1 and/or BRCA2 Variant Carriers

Japan
National Cancer Institute (NCI)

Terminated

Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Papillary Renal Cell Carcinoma

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer

Recurrent Ovarian Carcinoma | Ovarian Neoplasm | Ovarian Clear Cell Tumor | Adnexal Mass | Ovarian Endometrioid Tumor | Ovarian Serous Tumor | Borderline Ovarian Epithelial Tumor

United States
Dezhou Hospital Qilu Hospital of Shandong University

Completed

Long-term Survival Outcomes of Total Thyroidectomy and Radioactive Iodine Therapy in Unilateral T3/T4 FTC

Follicular Thyroid Cancer | SEER Database Analysis
Medical Enterprises Ltd.

Terminated

Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors. (RITE-USA)

Urinary Bladder Cancer | Bladder Cancer | Malignant Tumor of Urinary Bladder | Bladder Neoplasm | Cancer of Bladder | Carcinoma in Situ of Bladder | Bladder Tumors | Cancer of the Bladder | Neoplasms, Bladder | Papillary Carcinoma of Bladder (Diagnosis) | BCG-Unresponsive Bladder Cancer

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer

Head and Neck Cancer

United States
Tongji Hospital
Chongqing University Cancer Hospital; Henan Cancer Hospital; Qilu Hospital of... and other collaborators

Not yet recruiting

A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary

Ovarian Clear Cell Carcinoma
University of Washington
National Cancer Institute (NCI)

Terminated

The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors

Ovarian Cancer | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Adenocarcinoma | Ovarian... and other conditions

United States
University Health Network, Toronto

Active, not recruiting

Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient (Pemb-HT)

Ovarian Cancer | Small Cell Carcinoma, Hypercalcaemic Type

Canada
Giuseppe Procopio

Not yet recruiting

Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma (REPRINT)

Collecting Duct Carcinoma | Renal Medullary Carcinoma | Bellini Carcinoma

Italy
Bradley A. McGregor, MD
Bristol-Myers Squibb; Exelixis

Recruiting

Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

Renal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Collecting Duct Renal Cell Carcinoma | Translocation Renal Cell Carcinoma | Unresectable Advanced Renal Cell Carcinoma | Metastatic Ncc Renal Cell Carcinoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors

Childhood Teratoma | Stage II Malignant Testicular Germ Cell Tumor | Stage III Malignant Testicular Germ Cell Tumor | Childhood Embryonal Tumor | Childhood Extracranial Germ Cell Tumor | Childhood Extragonadal Germ Cell Tumor | Childhood Malignant Ovarian Germ Cell Tumor | Childhood Malignant Testicular... and other conditions

United States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
National Cancer Institute (NCI)

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditions

United States, Puerto Rico, Guam
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Ovarian Seromucinous Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Fallopian Tube Mucinous Adenocarcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent... and other conditions

United States, Puerto Rico
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

Renal Cell Carcinoma | Cervical Cancer | Endometrial Cancer | Urothelial Carcinoma | Ovarian Cancer Recurrent

China
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma

Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma | Fumarate Hydratase Deficient Renal Cell Carcinoma | Succinate Dehydrogenase Deficient Renal Cell Carcinoma | Collecting Duct Renal...

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma

Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Kidney Medullary Carcinoma | Loss of INI 1 Protein Expression

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma

United States
M.D. Anderson Cancer Center

Recruiting

Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial

Metastatic Renal Cell Carcinoma | Metastatic Melanoma | Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Bone | Metastatic Urothelial... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Soft Tissue Sarcoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Osteosarcoma | Ewing Sarcoma | Recurrent Renal Cell Carcinoma | Refractory Malignant Solid Neoplasm | Rhabdomyosarcoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Malignant Solid Neoplasm | Recurrent Osteosarcoma | Recurrent... and other conditions

United States
Sumitomo Pharma America, Inc.

Terminated

A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors

Fallopian Tube Cancer | Primary Peritoneal Cancer | Urothelial Carcinoma | Renal Cell Carcinoma (RCC) | Platinum-resistant Ovarian Cancer (PROC) | Serous Epithelial Ovarian Cancer

United States, Canada
NewVac LLC
Janssen Pharmaceutica N.V., Belgium

Completed

Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy

Epithelial Ovarian Cancer | Non-small Cell Lung Cancer

Russian Federation
Paul Monk
Genentech, Inc.

Terminated

Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer

Kidney Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Novartis; National Comprehensive Cancer Network

Completed

Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma

Cholangiocarcinoma | Soft-tissue Sarcoma | Solid Tumors | Thyroid Cancer

United States
Ikena Oncology

Recruiting

Study of IK-595 in RAS- or RAF-altered Advanced Tumors

Colorectal Cancer | Pancreatic Cancer | Thyroid Carcinoma | Solid Tumor, Adult | Malignant Melanoma | Non-Small Cell Lung Carcinoma | BRAF Gene Mutation | Gliomas, Malignant | Ras (Kras or Nras) Gene Mutation | CRAF Gene Mutation

United States
Genentech, Inc.

Completed

Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer

Non-Small Cell Lung Cancer, Ovarian Cancer

Spain, United States
Roswell Park Cancer Institute

Completed

Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

DNA Analysis in Samples From Younger Patients With Germ Cell Tumors and Their Parents or Siblings

Testicular Seminoma | Testicular Yolk Sac Tumor | Childhood Malignant Ovarian Germ Cell Tumor | Childhood Malignant Testicular Germ Cell Tumor | Ovarian Embryonal Carcinoma | Ovarian Yolk Sac Tumor | Testicular Embryonal Carcinoma | Ovarian Choriocarcinoma | Ovarian Mixed Germ Cell Tumor | Testicular Choriocarcinoma and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Mucinous... and other conditions

United States, Korea, Republic of, Japan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer

Metastatic Urothelial Carcinoma | Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant | Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant | Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation | Infiltrating Bladder Urothelial Carcinoma With Squamous... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Fallopian Tube Transitional Cell Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Clear... and other conditions

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex Therapeutics

Recruiting

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Serous Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Recurrent Fallopian... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditions

United States
Imperial College London

Not yet recruiting

SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours (SUMMER)

Ovarian Neoplasms | Ovarian Cancer | Ovary Cancer | Germ Cell Tumor | Ovary Neoplasm | Germ Cell Cancer | Germ Cell Ovarian Cancer | Germ Cell Neoplasia
Genentech, Inc.

Completed

A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study

Metastatic Colorectal Cancer | Ovarian Cancer | Basal Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Lung Carcinoid Tumor | Metastatic Digestive System Neuroendocrine Tumor G1 | Paraganglioma | Pancreatic Polypeptide Tumor | Pancreatic Glucagonoma | Pancreatic Insulinoma | Recurrent Merkel Cell Carcinoma | Somatostatin-Producing Neuroendocrine Tumor | Stage IV Merkel Cell Carcinoma | Recurrent Digestive... and other conditions

United States
Bicara Therapeutics
Merck Sharp & Dohme LLC

Recruiting

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Head and Neck Neoplasms | Carcinoma, Squamous Cell | Colorectal Cancer | Squamous Cell Carcinoma of Head and Neck | Epithelial Ovarian Cancer | Head and Neck Squamous Cell Carcinoma | Pancreas Cancer | Squamous Cell Carcinoma of the Lung | Cutaneous Squamous Cell Carcinoma | Squamous Cell Carcinoma of... and other conditions

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditions

United States
University Hospital, Brest

Completed

Thyroid Dysfunction and Nivolumab Reponse in NSCLC (THYRONIVO)

Non Small Cell Lung Cancer Metastatic | Prognosis | Thyroid Dysfunction | Immune Checkpoint Inhibitor | Treatment Adverse Effect

France
Instil Bio

Active, not recruiting

ITIL-306 in Advanced Solid Tumors

Renal Cell Carcinoma | Epithelial Ovarian Cancer | Non-small Cell Lung Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI); Eastern Cooperative Oncology Group

Completed

Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer

Stage III Uterine Corpus Cancer | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma | Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation

United States
AstraZeneca

Recruiting

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC (SAMETA)

Papillary Renal Cell Carcinoma

China, Czechia, Israel, Netherlands, Spain, United Kingdom, Korea, Republic of, Italy, India, Mexico, Turkey, Argentina, Australia, Canada, Germany, Russian Federation, Taiwan, United States, Poland, Brazil, Chile, Hong Kong, Ukraine, Franc... and more
National Cancer Institute (NCI)

Completed

A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer

Kidney Cancer

United States
First Affiliated Hospital, Sun Yat-Sen University

Not yet recruiting

Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy

Papillary Renal Cell Carcinoma
ARCAGY/ GINECO GROUP
Merck Sharp & Dohme LLC

Recruiting

Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT (PembroSCCOHT)

Small Cell Ovarian Carcinoma

France
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Fallopian... and other conditions

United States, Puerto Rico
Oncorena AB

Recruiting

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

Carcinoma, Renal Cell

Sweden
Genelux Corporation
GOG Foundation

Recruiting

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Fallopian Tube Cancer | Platinum-resistant Ovarian Cancer | Platinum-refractory Ovarian Cancer | Primary Peritoneal Cancer | High-grade Serous Ovarian Cancer | Endometrioid Ovarian Cancer | Ovarian Clear Cell Carcinoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors

Testicular Yolk Sac Tumor | Recurrent Ovarian Germ Cell Tumor | Recurrent Childhood Malignant Germ Cell Tumor | Recurrent Malignant Testicular Germ Cell Tumor | Childhood Extracranial Germ Cell Tumor | Childhood Malignant Ovarian Germ Cell Tumor | Childhood Malignant Testicular Germ Cell Tumor | Ovarian... and other conditions

United States, Canada, Australia, Puerto Rico

Clinical Trials on Columnar Cell Variant Thyroid Gland Papillary Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations